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Influenza viruses are common respiratory patho-
gens associated with considerable morbidity and 
mortality worldwide (Cox and Subbarao, 2000). 
Influenza A viruses primarily infect respiratory 
epithelial cells and replicate to produce large 
numbers of progeny virus that can then infect 
alveolar macrophages. Within hours, alveolar 
macrophages produce proinflammatory cyto-
kines and chemokines, leading to the migration 
of peripheral blood DCs as well as lymphocytes 
to the site of infection, and their subsequent   
activation (La Gruta et al., 2007).
Influenza virus infection induces both type 1   
and 2 (T1 and T2, respectively) immune re-
sponses (Doherty et al., 2006; La Gruta et al., 
2007). T1 immunity, characterized by high lev-
els of IFN- and TNF, is predominantly in-
duced by DCs and macrophages, and results in 
the generation of various effector cells, includ-
ing Th1 T cells and CTLs, that invoke cell- 
mediated protective immunity (Doherty et al., 
2006; La Gruta et al., 2007). The contributions of 
T2 immune responses to effective recovery from 
influenza virus infection are well recognized: 
Th2 T cell–directed expansion, differentiation, 
and isotype switching of B cells results in the 
production of neutralizing antibodies (Clements 
et al., 1986; Garcon et al., 1990; Marshall et al., 
1999). These antibodies have a pivotal role in 
viral clearance and protection from secondary 
infection (Palladino et al., 1995; Renegar et al., 
2004). Influenza virus–induced T2 immune re-
sponses are also linked to immunopathology in 
primary infection. Pulmonary eosinophilia, a 
classical  T2  inflammatory  response  associated 
with influenza virus infection (van der Klooster 
et al., 2004; Buchweitz et al., 2007), can be in-
duced by T2 proinflammatory cytokines such as 
IL-5 and eotaxin when expressed in lung tissues 
and is exacerbated after adoptive transfer of   
antiinfluenza Th2 T cell clones (Graham et al., 
1994; Roboz and Rafii, 1999; Fort et al., 2001; 
Hurst  et  al.,  2002).  Influenza  virus  infection 
may also induce nonrespiratory complications, 
including postinfectious encephalitis (La Gruta 
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Antiinfluenza type 2 (T2) immunity contributes to both immunopathology and immunopro-
tection, yet the underlying mechanisms modulating T2 immunity remain ill defined. We 
describe a novel mouse antigen (Ag)-presenting cell (APC), designated late-activator APC 
(LAPC). After pulmonary influenza A (H1N1) virus infection, LAPCs enter the lungs, capture 
viral Ag, and subsequently migrate to the draining lymph node (DLN) and spleen, with 
delayed kinetics relative to dendritic cells (DCs). In the DLN, influenza virus–activated 
LAPCs present Ag and selectively induce T helper type 2 (Th2) effector cell polarization  
by cell–cell contact–mediated modulation of GATA-3 expression. In adoptive transfer 
experiments, influenza virus–activated LAPCs augmented Th2 effector T cell responses in 
the DLN, increased production of circulating antiinfluenza immunoglobulin, and increased 
levels of T2 cytokines in bronchoalveolar lavage fluid in recipient influenza virus–infected 
mice. LAPC-recipient mice exhibited exacerbated pulmonary pathology, with delayed viral 
clearance and enhanced pulmonary eosinophilia. Collectively, our results identify and  
highlight the importance of LAPCs as immunomodulators of T2 immunity during influenza  
A virus infection.
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significant difference in LAPC numbers between Rag-1/ 
and Rag-1+/+ mice (P = 0.198), from which we infer that 
these cells are not mature lymphocytes.
To determine whether LAPCs originate from either DCs 
or NK cells, the number of splenic LAPCs was compared be-
tween Flt3L/ or IL-15/ mice and their WT littermates. 
Flt3L/ mice exhibit a selective defect in both DC and NK 
cell development, and IL-15/ mice exhibit a selective de-
fect in NK cell development (unpublished data; Kennedy   
et al., 2000; McKenna et al., 2000). However, we identified no 
significant decrease in LAPC numbers in the spleens of these 
Flt3L/ and IL-15/ mice compared with WT littermates 
(Fig. 1 D). Rather, in these mice, we detected an increase in 
LAPC numbers in spleens. As for Id2/ mice, for which Id2 
is a critical determining factor for NK cell and DC develop-
ment, thereby leading to a selective defect in the develop-
ment of Langerhans cells and CD8+ DCs, but skewing the 
phenotype toward increased numbers of mature B cells in the 
periphery (Becker-Herman et al., 2002; Hacker et al., 2003), 
this increase in splenic LAPC numbers may be a consequence 
of skewing of lineage-determinant factors. Our results sug-
gest that LAPCs follow a different developmental pathway to 
that of either DCs or NK cells.
To further delineate the relationship of LAPCs to other 
immune cell types, gene expression analysis was performed 
comparing the expressed signature gene profile of LAPCs 
with other immune cell types. LAPCs were isolated from the 
mediastinal DLNs of either mock (PBS) or A/WSN/33 in-
fluenza virus–infected mice (500 PFU, intranasal) on day 8 
after infection. Cells were lysed, RNA extracted, and pro-
cessed for analysis by the Affymetrix GeneChip platform. Using 
public databases, we compared the gene expression profiles   
of LAPCs with other mouse immune cell types, including   
B cells, CD4+ T cells, CD8+ T cells, NK cells, CD11b+ con-
ventional DCs (cDCs), CD8+ cDCs, pDCs, macrophages, 
granulocytes, and mast cells. Unsupervised hierarchical clus-
tering analysis of 36,290 probe sets across 11 different cell 
types  was  performed  using  GeneSpring  analysis  software   
(version 10). This global gene expression profile compari-
son revealed several biological trends (Fig. 2). Overall, the 
phylogenetic tree replicated previous results by Robbins et al. 
(2008) in relation to the cell-type comparisons performed in 
this study. Three main subbranches occur, which fall across 
three biological classifications: lymphocytes, DCs, and my-
eloid cells. According to this clustering scheme, LAPCs fall 
into the myeloid lineage and are most similar in gene expres-
sion profile to granulocytes.
We next undertook to compare the signature gene ex-
pression profiles between LAPCs and each individual immune 
cell type. Notably, these direct comparisons between LAPCs 
and 10 other immune cell types revealed a distinguishable 
gene expression signature for LAPCs, distinct even from gran-
ulocytes (Table S1). Of note, because LAPCs show no CD3 
or pre-TCR gene expression, this is in further support that 
LAPCs differ in their origin from lymphocytes and DCs 
(Corcoran et al., 2003).
et al., 2007). In a mouse model of infection, the levels of   
T2 cytokines correlated directly with the severity of postin-
fectious encephalitis induced by primary influenza virus infec-
tion (Kaji et al., 2000). Viewed collectively, the data suggest 
that  T2  immunity  influences  both  immunoprotection  and 
immunopathology after influenza virus infection. However, 
the  mechanisms  modulating  antiinfluenza  T2  immune  re-
sponses remain poorly defined.
In this study, we describe a novel APC population in   
naive mice, designated late-activator APCs (LAPCs; mouse 
plasmacytoid DC [pDC] antigen [Ag] 1 [mPDCA-1]+CD11c 
TCRB220CD38+CD44intCD45+Gr1+). Our morpho-
logical,  phenotypic,  and  genetic  characterizations  of  these 
LAPCs suggest that they are a unique cell population distinct 
from other immune cell types. In response to pulmonary in-
fluenza A virus infection, LAPCs function as APCs in the 
draining LN (DLN) and spleen. In contrast to DCs, LAPCs 
exhibit delayed kinetics of migration to the DLN, suggesting 
a distinct functional role in the DLN. Notably, LAPC traf-
ficking from infected tissues to the associated DLNs was   
also observed after respiratory infection with vaccinia virus 
(VACV) and cardiotropic infection with coxsackievirus B3 
(CVB3). In ex vivo studies, we provide evidence that influ-
enza virus–activated LAPCs in the DLN induce Th2 effector 
cell polarization. In vivo adoptive transfer experiments con-
firmed that influenza virus–activated LAPCs selectively in-
duce both systemic and local antiinfluenza virus T2 immunity 
in mice. Viewed collectively, the data suggest that these novel 
APCs may play a pivotal role in modulating antiinfluenza T2 
immunity during acute virus infection.
RESULTS
Identification of LAPCs in mice
As previously described (Blasius et al., 2006), the anti–
mPDCA-1  mAb  recognizes  Ag  expressed  on  pDCs 
(CD11cintB220+CD11blow/CD8low/CD4+Gr1+)  and  some 
B  (B220+CD19+)  and  CD4+  T  (CD4+CD8CD49bTCR+) 
lymphocytes (Fig. 1 A and not depicted). Interestingly, in LNs 
from naive C57BL/6J mice, we identified another mPDCA-1 
Ag–positive cell population, defined in this study as LAPCs, 
that is CD11c, TCR, and B220 (Fig. 1 B). Further phe-
notypic characterization of these LAPCs revealed that this cell 
population is CD38+, CD44int, CD45+, and Gr1+ (Fig. 1 C). 
LAPCs  (mPDCA-1+CD11cTCRB220CD38+CD44int
CD45+Gr1+) were also detected in the spleens of naive mice 
and exhibited an identical pattern of cell-surface marker ex-
pression to LN-derived LAPCs (unpublished data).
Because CD38 and CD44 are markers for B and T lym-
phocytes, respectively (Oliver et al., 1997; Maiti et al., 1998), 
we  examined  whether  LAPCs  represent  a  developmental 
stage  of  lymphocytes  by  using  splenocytes  from  Rag-1 
knockout mice (Rag-1/) and their WT littermates (Rag-1+/+; 
Fig. 1 D). Despite major defects in lymphocyte development 
(unpublished  data),  in  replicate  experiments  we  identified 
LAPCs in Rag-1/ mice with <100,000 cells detected 
per  spleen.  Moreover,  statistical  analysis  revealed  no   JEM VOL. 207, July 5, 2010 
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not conform with that of granulocytes. In agree-
ment with our purity data (>97% with <1% con-
tamination  with  CD11c+;  unpublished  data), 
LAPCs present as a homogeneous cell population 
with morphological characteristics of plasmacytoid 
cells, namely a round shape, distinct from DCs 
(pDCs, mPDCA-1+CD11cint; cDCs, CD11chigh 
B220) and B (B220+CD19+) and T (TCR+) 
lymphocytes  (Fig.  3,  A  and  B).  LAPCs  have  a 
smooth plasma membrane with no pseudopodia. 
The cytoplasm has no granules, fewer organelles 
(vacuoles and mitochondria), and a denser appear-
ance than DCs. There is also a marked difference 
in the shape of the nuclei between LAPCs and 
DCs, with LAPC nuclei being uniformly large and 
round. Viewed collectively, these data distinguish 
LAPCs from PMNs, granulocytes, DCs, macro-
phages, lymphocytes, and NK cells.
In an attempt to identify LAPC-specific genes, 
another round of gene expression analysis was per-
formed. 279 genes were identified that displayed   
a 10-fold difference in expression level between 
LAPCs and any other immune cell lineage in at 
least 5 out of the 10 possible comparisons (unpub-
lished data). Further analysis provided a list of   
20 gene candidates apparently not expressed by other 
immune cell types (Affymetrix intensity value < 100) 
except LAPCs (Affymetrix intensity value > 100; 
Fig. S2). Interestingly, this list includes some re-
production-related  genes  such  as  Oosp1,  Plac1l, 
and Pp11r. In addition, several membrane-bound ion chan-
nel–related genes were identified, including Cacna1h and At-
p6v0a1. Reln (extracellular matrix serine protease), which is 
Although  LAPCs  express  the  neutrophil  marker  Gr1 
(Fleming et al., 1993) and are most similar to granulocytes in 
their global gene expression profile, their morphology does 
Figure 1.  Phenotypic characterization of LAPCs. Ingui-
nal and axillary LNs were harvested from naive C57BL/6J 
mice aged 8–12 wk, and single-cell suspensions were pre-
pared and processed for flow cytometry as described in Ma-
terials and methods. (A) Lineage-specific markers were 
examined on pDCs (open histograms). Staining with isotype-
matched control antibodies was included (black histograms; 
n = 3 mice). (B) TCRB220 cells were characterized  
using mPDCA-1– and CD11c-specific mAbs. Isotype control 
staining is also shown (n = 3 mice). (C) LAPCs (mPDCA-
1+CD11cTCRB220) were stained with antibodies specific 
for the indicated surface markers (open histograms). Staining 
with isotype-matched control antibodies was included  
(black histograms; n = 3 mice). For A–C, representative stain-
ing from at least five independent experiments (n = 3 for each 
experiment) is shown. (D) Splenocytes were isolated from  
the indicated gene-targeted mice and WT C57BL/6J mice  
(n = 5 each), and stained for markers of LAPCs (mPDCA-1+ 
CD11cTCRB220). LAPCs are recorded as absolute cell 
numbers (means ± SEM) in total splenocytes based on their 
percentage in the total cell population. Data are representa-
tive of two independent experiments and were analyzed 
using a Student’s t test. A.H IgG, Armenian hamster IgG.1438 A novel APC implicated in antiviral Th2 immunity | Yoo et al.
including BM, LNs, and spleens in naive C57BL/6J 
mice (Table I). Notably, in spleens, the cell num-
bers are comparable to pDCs. LAPCs were identi-
fied in all mouse strains we have screened, including 
BALB/c, A/J, and DBA/2J mice (Fig. S3).
LAPCs are APCs responding to virus infection
LAPCs derived from LNs express both MHC-II 
(I-A/E)  and  co-stimulatory  molecules  such  as 
CD40, CD80, and CD86, although expression 
levels are lower than identified for DCs (Fig. 4 A). 
Splenic LAPCs exhibit a similar pattern of cell-
surface Ag expression, albeit MHC-II, CD40, and 
CD80 levels are modestly higher (mean fluores-
cence intensity [MFI] = 467 ± 145, 63 ± 19, and 
83  ±  25,  respectively;  unpublished  data)  com-
pared with their expression levels on LAPCs de-
rived from LNs (MFI = 177 ± 9, 14 ± 1, and   
28 ± 4, respectively).
To examine the effects of virus infection on the 
activation and migration of LAPCs, mice were in-
tranasally instilled with a sublethal dose (500 PFU) 
of influenza virus (A/WSN/33). In time-course 
studies, we observed that LAPCs in the DLN (me-
diastinal  LN)  up-regulated  surface  expression  of 
MHC-II, CD40, and CD86 molecules in a similar 
manner to both pDCs and cDCs (Fig. 4 B). How-
ever, the expression levels of these co-stimulatory 
molecules on LAPCs were lower than identified 
for DCs on day 3 after infection. Notably, LAPCs were de-
tected in the secondary lymphoid tissues (LNs and spleen) of 
both  naive  and  A/WSN/33  influenza  virus–infected  mice 
(day3), together with cDCs and pDCs, as a distinct population 
in the contour plots of CD11c and MHC-II coexpression, in 
further support that LAPCs are a unique population distinct 
from DCs (Fig. 4 C).
In response to pulmonary influenza A virus infection, the 
population of LAPCs increased in the lungs early after infec-
tion (approximately day 3 after infection) and declined there-
after. A significant increase in LAPCs in the DLN and spleen, 
but not in the nondraining LNs (inguinal and axillary LNs), 
was observed later after infection, on day 6 (Fig. 4, D and E). 
Notably, the greatest number of LAPCs in the DLN and spleen 
was observed on day 8 after infection, whereas, as previously 
one of the key neuronal proteins regulating brain develop-
ment, is also highly expressed by LAPCs regardless of their 
activation status. Moreover, Tnfrsf17/Bcma, most commonly 
associated with plasma cells, was identified, even though our 
gene expression data and results from the Rag-1/ mice 
studies suggest that LAPCs are not mature B lymphocytes. In 
preliminary studies examining expression of BCMA and 
Plac1l by FACS, we confirmed that LAPCs express both,   
albeit at low levels (unpublished data). The combination of 
these cell surface–expressed factors and mPDCA-1, CD38, 
CD44, CD45, and Gr1 in the absence of CD11c, TCR, 
B220, and CD19 further support the evidence that LAPCs 
are distinct from other immune cell types.
Further screening for this rare cell population revealed 
that LAPCs populate peripheral blood and lymphoid tissues 
Figure 2.  LAPCs exhibit a unique gene expression sig-
nature. Two-way unsupervised hierarchical clustering anal-
ysis using microarray gene expression data for multiple 
immune cell types, including LAPCs. Data are visualized col-
orimetrically with heat plots (red represents elevated gene 
expression and green represents decreased gene expression). 
The color scale for relative expression values as obtained 
after log2 transformation and median centering of the val-
ues across samples for each gene is given below the heat 
map. The experimental analysis was performed as described 
in Materials and methods.JEM VOL. 207, July 5, 2010 
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were  seen  in  mock-infected  (FITC-dextran,  CFSE, 
IMDM, and PBS) mice (Fig. 5, B and D; and not de-
picted). In addition, we did not observe any sex differ-
ences  in  the  activation  of  LAPCs  by  influenza  virus 
infection, because both male and female mice showed 
similar levels of cell infiltration into the DLN (unpub-
lished data). Influenza virus–activated LAPCs on day 8 
after infection showed identical surface marker expres-
sion to that of naive LAPCs (unpublished data) and did 
not exhibit morphological changes beyond enlargement 
(unpublished data).
Given that chemokines regulate leukocyte recruit-
ment to the lung during the early phase of influenza 
infection, and the evidence that CXCR3–CXCL10 
interactions  influence  this  trafficking  (Dawson  et  al., 
2000; Wareing et al., 2004; La Gruta et al., 2007), we 
examined  bronchoalveolar  lavage  (BAL)  fluid  for 
CXCL10 production and LAPCs for CXCR3 expres-
sion. CXCL10 was detectable in the lungs from day 3 after 
infection, with maximal production on day 6 (Fig. S4 A). 
In naive mice, circulating LAPCs express CXCR3 on 
their surface. Early (day 3) in influenza virus infection, 
LAPCs infiltrating the lung continue to express CXCR3. 
However, CXCR3 expression was significantly down-
regulated by day 6 after infection in lung-derived LAPCs 
and could not be detected on LAPCs in the DLN 
(Fig. S4 B). These results suggest that the early inflam-
mation in influenza virus–infected lung tissue might   
induce  the  infiltration  of  circulating  LAPCs  into   
the lungs, presumably mediated by CXCR3–CXCL10– 
induced chemotaxis. Subsequently, influenza virus–activated 
LAPCs down-regulate CXCR3 expression and thereafter 
migrate to the DLN.
To determine the potential of LAPCs to function as APCs 
in the DLN, we performed a direct ex vivo Ag detection 
(DEAD) assay. C57BL/6J mice were instilled intranasally 
(500 PFU) with either WT influenza A virus (A/WSN/33) 
or  recombinant  virus  expressing  MHC-II–restricted  OVA 
peptide (323–339; A/WSN/OVA(II)). On day 3 after infec-
tion, one group of mice was sacrificed and DCs (cDCs and 
pDCs) were harvested from the DLN, and on day 8 after in-
fection, the remaining mice were sacrificed and LAPCs were 
harvested from the DLN. Naive OT-II T cells were cultured 
with either day 3 DCs or day 8 LAPCs, which were then ei-
ther restimulated at 96 h with PMA and ionomycin, or not. 
reported (Yoneyama et al., 2005), DCs were most abundant in 
the DLN on day 3 after infection.
Although we cannot rule out the possibility that influenza 
virus–activated LAPCs may proliferate in the lungs or DLN, 
our data from in vivo Ag uptake (FITC-dextran; Fig. 5,   
A and B) and migration (CFSE; Fig. 5, C and D) experiments 
suggest that lung-infiltrated LAPCs capture viral Ags and mi-
grate to the DLN and spleen in response to influenza virus 
infection, presumably to stimulate cognate CD4+ T cells. In 
Rag-1/, Flt3L/, and IL-15/ mice infected intranasally 
with 250 PFU of influenza A virus, we could still observe 
significant LAPC infiltration into the spleen, further corrob-
orating that these cells are neither lymphocytes, DCs, nor 
NK cells (unpublished data). LAPC migration to the lungs, 
DLN, and spleen was a specific response to inflammation in-
duced by influenza A virus infection, because no infiltrates 
Figure 3.  Morphological characterization of LAPCs in naive 
mice. (A) Representative images of the indicated cell types: LAPCs 
(mPDCA-1+CD11cTCRB220), pDCs (mPDCA-1+CD11cint), cDCs 
(CD11chighB220), B cells (B220+CD19+), and T cells (TCR+). Each cell 
population was FACS sorted from either LNs or spleens isolated 
from naive C57BL/6J mice, cytocentrifuged, and stained with modi-
fied Wright-Giemsa. (B) Representative ultrastructure details of 
freshly isolated LAPCs, cDCs, and pDCs using transmission electron 
microscopy. Representative images from two independent experi-
ments are shown.1440 A novel APC implicated in antiviral Th2 immunity | Yoo et al.
Figure 4.  LAPCs exhibit characteristics of APCs responding to pulmonary influenza virus infection. (A) LN single-cell suspensions from naive 
C57BL/6J mice (n = 3) were stained with antibodies specific for MHC-II (I-A/E), CD40, CD80, and CD86. Histograms are gated on LAPCs (mPDCA-1+ 
CD11cTCRB220; continuous line open histograms), pDCs (mPDCA-1+CD11cint; dashed line open histograms), and cDCs (CD11chighB220; gray histo-
grams). Staining with isotype-matched control antibodies was included (black histograms). Data are representative of three independent experiments.  
(B) C57BL/6J mice (n = 15) were infected intranasally with 500 PFU of A/WSN/33 influenza virus. At the indicated times after infection, mice were sacri-
ficed and DLNs were harvested. Cells were collected and stained with the appropriate fluorochrome-conjugated mAbs to monitor surface expression of JEM VOL. 207, July 5, 2010 
Article
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LAPCs  from  A/WSN/OVA(II)  virus–infected  mice  acti-
vated OT-II T cells to produce IL-2 (Fig. 5 E). T cell activa-
tion was further confirmed by a [3H]thymidine incorporation 
assay, which demonstrated that influenza virus–activated 
LAPCs isolated from the DLN on day 8 after infection ex-
hibited equivalent activity to DCs harvested on day 3 after 
infection (Fig. S5).
To examine whether Ag presentation by LAPCs still 
occurs in mice with defects in DC development, another 
series of DEAD assays was performed using LAPCs isolated 
from  the  DLNs  of  influenza  virus–infected  (250  PFU) 
Flt3L/ mice. As shown in Fig. S6, LAPCs isolated from 
Flt3L/ mice on day 8 after infection presented viral Ag to 
cognate CD4+ T cells. Moreover, LAPCs from Flt3L/ 
mice (250 PFU) exhibited even higher Ag-presenting ca-
pacity than that of LAPCs from WT mice (500 PFU; Fig. 5 E), 
suggesting that LAPCs are indeed a unique APC popula-
tion distinct from DCs.
Next, we examined whether LAPCs respond to other   
virus infections. CVB3 induces myocarditis and dilated cardio-
myopathy in mice (Baboonian et al., 1997). C57BL/6J mice 
were infected with 10,000 PFU CVB3 by intraperitoneal in-
jection and then monitored on days 3 and 7 after infection for 
LAPC migration into the DLN (mediastinal LN). As with 
influenza virus infection, maximal infiltration of LAPCs was 
observed at the later time point, day 7 after infection (unpub-
lished data). As the vaccine agent for smallpox, VACV is one 
of the most well-characterized members of the poxvirus fam-
ily (Smith and Law, 2004). Using the recombinant strain 
Western Reserve VACV (10,000 PFU) to infect C57BL/6J 
mice by intranasal inoculation, we again observed LAPC mi-
gration to the DLN, with the greatest number detected by 
day 7 after infection (unpublished data). Viewed collectively, 
these data suggest that LAPCs are APCs distinct from DCs, 
responding to various virus infections including influenza   
virus, CVB3, and VACV.
Influenza virus–activated LAPCs localize in T cell zones  
of the DLN
To examine the localization of Ag-presenting influenza virus–
activated LAPCs in the DLN, an in vivo tracking experiment 
was performed using CFSE labeling. Influenza A virus–activated 
LAPCs isolated on day 6 after infection from the DLNs of 
mice were stained with CFSE in vitro and adoptively trans-
ferred by i.v. injection into influenza virus–infected recipient 
mice on day 6 after infection. 24 h after transfer, the DLNs were 
harvested from recipient mice and the localization of donor 
LAPCs was monitored by confocal microscopy (Fig. 6 A).   
As shown in Fig. 6 B, the majority of CFSE-labeled donor 
LAPCs localized to the T cell zone (B220 area) and some lo-
calized to the paracortex region (boundary of the B and T cell 
zones) of the DLN. However, few donor LAPCs localized to 
the B cell zone (B220+ area).
Influenza virus–activated LAPCs induce Th2 polarization  
of Ag-primed CD4+ T cells ex vivo
Given the localization of Ag-presenting LAPCs to the T cell 
zone in the DLN, we examined whether influenza virus– 
activated LAPCs are capable of modulating antiinfluenza CD4+   
T cell responses in the DLN. To do this, we designed a system 
to mimic T cell–LAPC interactions in the DLNs. Specifically, 
OT-II T cells were purified from naive Thy1.1+ OT-II mice 
and transferred into Thy1.2+ C57BL/6J mice (2–3 × 106 cells/
mouse) by i.v. injection.
24 h after adoptive transfer, recipient mice were infected 
by intranasal instillation with 500 PFU of A/WSN/OVA(II) 
virus. On day 5 after infection, after the accelerated migration 
of DCs from lung to the DLN and before the significant influx 
of LAPCs (Fig. 4 D), in vivo Ag-primed OT-II T cells 
(Thy1.1+CD4+) were isolated from the DLN and cultured to-
gether with either DCs or LAPCs sorted from the DLNs   
of either A/WSN/33 or A/WSN/OVA(II) influenza virus– 
infected mice harvested on day 8 after infection. 24 h after 
the indicated molecules for each cell population. Data are representative of two independent experiments and presented as MFI (means ± SD). (C) Single-
cell suspensions were isolated from each indicated lymphoid tissue from naive or A/WSN/33 influenza virus–infected C57BL/6J mice (D3) and stained with 
the appropriate fluorochrome-conjugated mAbs. The coexpression of MHC-II (I-A/E) and CD11c for each gated population (cDCs, pDCs, and LAPCs) is 
shown as contour plots. Data are representative of three independent experiments. (D) At the indicated times after infection, the abundance of LAPCs, 
pDCs, and cDCs in the DLN was monitored, presented as the percent population in total DLN cells (n = 5 mice at each time point). Representative staining 
from three independent experiments is shown. (E) At the indicated times after infection, the absolute numbers of LAPCs in the lungs (n = 7 at each time 
point), DLN (n = 5 at each time point), spleens (n = 6 at each time point), and nondraining inguinal and axillary LNs (NLNs; n = 6 at each time point) was 
monitored. Data are representative of three independent experiments and are shown as means ± SD.
 
Table I.  Percent population of LAPCs in different lymphoid tissues of naive C57BL/6J mice
LAPCs (mPDCA-1+CD11cTCRB220) pDCs (mPDCA-1+CD11cint) cDCs (CD11chighB220)
LNs (n = 12) 0.045 ± 0.006 0.075 ± 0.006 0.14 ± 0.02
Spleen (n = 12) 0.12 ± 0.01 0.11 ± 0.02 0.92 ± 0.1
PBMCs (n = 10) 0.13 ± 0.03 0.06 ± 0.02 0.06 ± 0.03
BM (n = 10) 0.45 ± 0.2
Thymus (n = 10) 0.02 ± 0.01
Data shown are means ± SD.1442 A novel APC implicated in antiviral Th2 immunity | Yoo et al.
Figure 5.  Influenza virus–activated LAPCs transport viral Ags from the lungs to the DLN and spleen for Ag presentation. (A) Sche-
matic diagram for in vivo Ag uptake assay. (B) Mice (n = 12) were infected intranasally with 500 PFU of A/WSN/33 virus with or without (negative 
control) FITC-dextran. On day 3 after infection, mice were sacrificed and FITC+ T cells, pDCs, and LAPCs were examined in the lungs from FITC-dextran–
instilled (open histograms) or control (black histograms) mice by FACS analysis. Numbers indicate the percentage of FITC+ cells within each popula-
tion. As additional controls, naive mice were instilled only with FITC-dextran or sterile PBS and sacrificed on day 3 after treatment. Dot plots are 
gated on the TCRB220 cell population in the lungs; the presence of LAPCs (mPDCA-1+CD11c) was monitored and compared with lung LAPCs 
derived from day 0 and 3 influenza virus–infected mice. Numbers indicate the percent population in total lung cells. Data are representative of two 
independent experiments. (C) Schematic diagram for in vivo migration assay. (D) Mice (n = 12) were infected with 500 PFU of A/WSN/33 virus. On 
day 4 after infection, mice received an intranasal instillation with either CFSE or carrier medium (sterile IMDM; negative control). At the indicated 
time points after infection, mice were sacrificed (n = 3 for each time point) and the CFSE+ LAPC population in the indicated tissues of CFSE- 
instilled (open histograms) or sterile IMDM-instilled (black histograms) mice was examined by FACS analysis. Numbers indicate the percentage of 
CFSE+ LAPCs. As additional controls, naive mice were instilled only with CFSE or sterile IMDM and sacrificed at 7 h after treatment. The presence 
of LAPCs was monitored and compared with lung LAPCs derived from day 0 and 4 influenza virus–infected mice. Numbers in dot plots show the 
percent population in total lung cells. Data are representative of two independent experiments. (E) Mice were infected with 500 PFU of A/WSN/33 
(n = 15) or A/WSN/OVA(II) (n = 15) virus. On day 3 after infection, mice were sacrificed and DCs (cDCs and pDCs; n = 10 mice) were isolated from 
the DLN. On day 8 after infection, LAPCs (n = 5 mice) were isolated from the DLN. Naive OT-II T cells were cultured with day 3 DCs or day 8 LAPCs. 
IL-2 production from OT-II cells was examined on day 4 after incubation by intracellular cytokine staining. The horizontal dotted lines indicate the 
gate above which the IL-2–positive cell population is defined relative to the rat IgG2b isotype control. Representative staining from at least three 
independent experiments is shown. A.H IgG, Armenian hamster IgG.JEM VOL. 207, July 5, 2010 
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incubation, the generation of effector CD4+ T cells was exam-
ined by intracellular FACS staining for both IFN- and IL-4.
When isolated on day 5 after infection, >91% of the in vivo   
Ag-primed  OT-II  T  cells  exhibited  an  activated  pheno-
type, expressing elevated levels of CD44 and CD69 and de-
creased  levels  of  CD62L  compared  with  naive  OT-II   
T cells. Approximately 80% of these in vivo primed OT-II   
T cells exhibited an effector (CD44highCD62Llow) or memory 
(CD44highCD62Lhigh) phenotype (Fig. 7 A), and 6% had 
differentiated into IFN-–producing Th1 effector cells (Fig. 
7  B),  presumably  mediated  by  the  cognate  interaction 
with influenza virus–activated DCs in the DLN at an early   
phase of influenza A virus infection (Cella et al., 2000;   
GeurtsvanKessel et al., 2008). When co-cultured for 24 h 
with either DCs (CD11c+TCR) or LAPCs (mPDCA-1+ 
CD11cTCRB220)  derived  from  A/WSN/33  or   
A/WSN/OVA(II)  virus–infected  mice,  a  proportion  of  in 
vivo Ag-primed OT-II T cells differentiated into Th2 effector 
cells producing both IL-4 and IL-10 (Fig. 7 C). For optimal 
Th2 polarization, the cognate interaction with Ag-presenting 
LAPCs derived from A/WSN/OVA(II) virus–infected mice 
was required. However, there was no additive effect on Th2 
polarization by incubation with DCs derived from A/WSN/
OVA(II) virus–infected mice compared with DCs from   
A/WSN/33 virus–infected mice. Moreover, OT-II T cells 
incubated with LAPCs from A/WSN/OVA(II) virus–infected 
mice showed a higher capacity for Th2 polarization compared 
with OT-II T cells incubated with DCs from the same mice. 
Collectively, the data suggest that DCs in the DLN on day 8 
after infection may not present viral Ag to CD4+ T cells but 
that LAPCs may function as APCs by modulating antiinflu-
enza Th2 effector T cell responses in the DLN at this later 
time point after infection.
This result was further confirmed using only activated 
OT-II T cells. On day 5 after infection, OT-II T cells exhibiting 
an  activated  phenotype  (CD44highCD62Lhigh,  CD44high 
CD62Llow,  and  CD44intCD62Llow)  were  sorted  from  the 
DLNs and incubated together with -irradiated LAPCs from 
A/WSN/OVA(II) virus–infected mice (Fig. S7 A). Th2 po-
larization  of  Ag-primed  OT-II  T  cells  was  examined  by 
FACS analysis. As anticipated, 4% of Ag-primed OT-II   
T cells differentiated into a Th2 effector phenotype upon in-
cubation  with  influenza  virus–activated  LAPCs  presenting 
cognate Ag (Fig. S7 B).
Soluble factors, possibly produced by influenza virus– 
activated LAPCs, may be dispensable for LAPC-mediated Th2 
polarization, because LAPCs modulated Th2 polarization de-
spite  irradiation (2,000 rads; Fig. 7 C). This was further sup-
ported by Transwell experiments providing evidence that 
cell–cell contact is necessary for LAPC-mediated Th2 polariza-
tion (Fig. 7 E). Furthermore, influenza virus–activated LAPCs 
selectively induced GATA-3 expression, the master regulator 
controlling  Th2  differentiation  (Zheng  and  Flavell,  1997), 
from Ag-primed OT-II T cells (Fig. 7 D). Notably, T-bet ex-
pression in OT-II T cells was not modulated by incubation with 
LAPCs. The ability of LAPCs to promote Th2 polarization is 
further supported by our observation that maximal Th2 polar-
ization in vivo coincided temporally (day 8) with maximal 
LAPC infiltration into the DLN after influenza A virus infec-
tion (unpublished data). Moreover, LAPCs may express the 
thymic stromal lymphopoietin receptor (TSLPR), which is 
implicated in regulating the induction of T2 immunity in both 
the human and mouse systems (Ziegler and Liu, 2006), at a 
comparable level to that observed in DCs in naive mice. No-
tably, Tslpr gene expression was down-regulated in LAPCs on 
day 8 after influenza virus infection (Table S1). The contribu-
tion  of  TSLP–TSLPR–mediated  events  to  LAPC-induced 
Th2 polarization in our influenza A virus infection model   
remains to be clarified. Collectively, these results suggest that   
influenza virus–activated LAPCs induce Th2 effector cell po-
larization of Ag-primed CD4+ T cells through cell–cell contact– 
mediated selective modulation of GATA-3 expression coordi-
nated with TCR signaling.
Influenza virus–activated LAPCs modulate antiinfluenza  
T2 immunity in vivo
The role of LAPCs in modulating antiinfluenza virus T2   
immunity was further examined by in vivo adoptive transfer 
experiments. Either influenza A virus–activated LAPCs or 
Figure 6.  Influenza virus–activated LAPCs localize to the T cell 
area in the DLN. (A) Mice (n = 10) were infected intranasally with 500 PFU 
of A/WSN/33 virus, and on day 6 after infection, LAPCs were isolated 
from the DLNs. These LAPCs were CFSE labeled and adoptively transferred 
(106 cells/mouse) into recipient A/WSN/33 virus–infected (500 PFU) mice 
(day 6 after infection; n = 2). (B) 24 h after adoptive transfer, mice were 
euthanized and the DLNs were harvested and processed as described in 
Materials and methods for confocal microscopy. Representative images of 
two independent experiments are shown.1444 A novel APC implicated in antiviral Th2 immunity | Yoo et al.
Weight loss was monitored on a daily 
basis. DC- and LAPC-recipient mice 
exhibited  less  weight  loss  than  the 
PBS control mice (Fig. 8 B). On day 
8 after infection, all mice were eutha-
nized and tissues were harvested for 
analysis. Consistent with the ex vivo 
experimental data described in Fig. 7, donor LAPCs aug-
mented  the  Th2  effector  T  cell  response  in  the  DLNs   
without affecting either the Th1 or CTL responses in the 
DLNs and BAL (Fig. 8 C). Moreover, the data indicate that 
donor DCs specifically enhance antiinfluenza CTL responses 
in the DLNs and BAL (Fig. 8 C). DC- and LAPC-recipient 
DCs were isolated from the DLNs and spleens of mice on 
day 8 after infection (300 PFU), and transferred into recipi-
ent influenza A virus–infected mice (300 PFU) by i.v. injec-
tion on days 1 (3 × 105cells/mouse) and 3 (5 × 105cells/mouse) 
after infection (Fig. 8 A). A control group of recipient mice 
received only sterile PBS by i.v. injection, also on days 1 and 3.   
Figure 7.  Influenza virus–activated 
LAPCs induce Th2 effector cell polariza-
tion ex vivo. CD4+ T cells were isolated from 
naive Thy1.1+ OT-II mice and transferred into 
C57BL/6J (Thy1.2+) recipient mice (2–3 × 106 
cells/mouse) by i.v. injection. 24 h after adop-
tive transfer, recipient mice were infected 
intranasally with 500 PFU of A/WSN/OVA(II) 
virus. On day 5 after infection, recipient mice 
(n = 20) were sacrificed and donor T cells 
(Thy1.1+CD4+) were sorted from the DLN.  
(A) The activation markers expressed on 
sorted donor OT-II T cells (D5T, day 5) were 
compared with those on naive OT-II T cells (D0T, 
day 0) by flow cytometry. Representative images 
of three independent experiments are shown. 
(B) IL-4 and IFN- expression in D0T and D5T 
was examined by intracellular cytokine stain-
ing. Representative images of three indepen-
dent experiments are shown. (C and D) D5T 
(105 cells/well) were cultured with live or  
-irradiated (ir.) LAPCs (L; 5 × 104 cells/well) 
isolated from the DLN of A/WSN/33 (w) or  
A/WSN/OVA(II) virus (o)–infected C57BL/6J 
mice on day 8 after infection. -Irradiated 
DCs (CD11c+TCR; ir.D) isolated from the 
same DLNs were used as controls. At 24 h 
after incubation, IL-4, IL-10, and IFN- pro-
duction (C) and GATA-3 and T-bet expression 
(D) were examined in the D5T (Thy1.1+CD4+) 
population. Representative images of at least 
three independent experiments are shown.  
(E) D5T were incubated alone or together with 
day 8 LAPCs derived from A/WSN/OVA(II) virus–
infected mice (L (o)) with or without a Tran-
swell (tw) for 24h. D5T IL-4 expression was 
measured by intracellular cytokine staining. 
The horizontal dotted lines indicate the gate 
above which the IL-4–positive cell population 
is defined relative to the rat IgG1 isotype 
control. Data representative of three indepen-
dent experiments are shown as means ± SEM 
and were analyzed using a Student’s t test.  
*, P < 0.05 compared with D5T only; **, P < 0.05 
compared with D5T incubated with either  
L (w) or ir.L (w).JEM VOL. 207, July 5, 2010 
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(c-KitCD34CD49bCD54+Gr1+FcR1CD69low/ 
Thy1.2) from either lymphoid or myeloid progenitor cells 
(CD34+), basophils (c-KitCD49b+CD54+Gr1FcR1+),   
and the recently indentified natural helper cells (c-Kit+CD69+ 
Gr1Thy1.2+; Fig. 1 C and Fig. S1; Kondo et al., 1997, 2003; 
Sokol et al., 2009; Moro et al., 2010). Finally, LAPCs are BM-
derived nongranular leukocytes with plasmacytoid morphol-
ogy, likely of myeloid lineage. Neither influenza virus–activated 
nor IFN-– (10 ng/ml) and LPS-stimulated (1 µg/ml) LAPCs 
express iNOS, which further excludes the possibility that 
LAPCs are macrophages (Table S1 and unpublished data).
After pulmonary influenza A virus infection, LAPCs are 
detected in the lungs, likely a consequence of their migration 
out of the circulation mediated by CXCR3–CXCL10 inter-
actions. In contrast to DCs, LAPCs exhibited delayed kinetics 
of migration from the lungs into the DLN, suggesting that 
they may have a distinct role in an immune response to virus 
infection. Notably, LAPCs were also identified in the DLNs 
of VACV- and CVB3-infected mice. Bréhin et al. (2008) 
have identified a similar cell type in lymphoid tissues from 
West Nile virus–infected BALB/c mice. This cell population, 
isolated from LNs on day 6 after infection, exhibited surface 
CD19 expression comparable to that of B cells. We have ob-
served that, in contrast to LAPCs derived from naive mice, 
influenza virus–activated LAPCs exhibit only transient ex-
pression of CD19, on day 6 after infection, comparable to that 
of B cells (unpublished data).
As professional APCs in the immune system, DCs are re-
sponsible for initiating adaptive immune responses in lym-
phoid tissues (Banchereau et al., 2000). Certainly, during 
influenza virus infection, DCs play a key role in modulating 
adaptive T cell responses in both the lungs and the DLNs 
(Yoon et al., 2007; GeurtsvanKessel et al., 2008; McGill et al., 
2008). Influenza A virus infection induces the maturation of 
DCs in the lungs, and DCs then migrate to the DLN to pres-
ent viral Ags to virus-specific T cells (Yoon et al., 2007; 
GeurtsvanKessel et al., 2008). Additionally, a resident subset 
of DCs (CD11bCD8+ DCs) in the DLN can also present 
viral Ags to CD8+ T cells for up to 12 d after infection (Belz 
et al., 2004, 2007). However, it has been suggested that Ag 
presentation to CD4+ T cells is restricted to the migrating 
DCs, whose accelerated migration is transient during the early 
phase of infection (before day 2), and these DCs have a   
limited half-life in the DLN (Legge and Braciale, 2003; 
GeurtsvanKessel et al., 2008). In this study, we also observed 
that DCs isolated from the DLN and spleen on day 8 after in-
fection are capable of stimulating antiinfluenza CTL responses, 
presumably by presenting viral Ag to cognate CD8+ T cells, 
with no evidence for Ag presentation to CD4+ T cells (Fig. 7 C 
and Fig. 8 C).
Influenza A virus infection induces both T1 and T2 T cell 
responses (Carding et al., 1993; Graham et al., 1994; La Gruta 
et al., 2007). Antiinfluenza T1 immunity, implicated in viral 
clearance in infected lung tissues, is induced by DCs during the 
early phase of infection, around day 3 after infection, in the 
DLN (Carding et al., 1993; Cella et al., 2000; GeurtsvanKessel 
mice  exhibited  elevated  serum  IgG2a,  IgG2b,  IgG1,  and   
IgA  production,  relative  to  the  PBS  controls,  with  se-
lectively enhanced IgE production in the LAPC-recipient 
mice (Fig. 8 D).
BAL cytokine production on day 8 after infection was 
examined by SearchLight proteome array analysis (Fig. 8 E). 
LAPC-recipient mice exhibited enhanced production of T2 
cytokines, including IL-4, IL-5, and eotaxin, relative to DC 
recipients and PBS controls. Recently, Sun et al. (2009) have 
reported that IL-10 is produced in influenza virus–infected 
lung tissue exclusively by infiltrating virus-specific T1 effec-
tor T cells (Th1 cells and CTLs), with CTLs contributing a 
significant portion of the total IL-10 produced. In agreement, 
even though the data are not statistically significant for IL-10, 
we observe that DC-recipient mice have augmented CTL 
responses in their lungs, exhibiting elevated levels of IL-10 
production compared with PBS controls (Fig. 8, C and E). 
However, LAPC-recipient mice do not show any difference 
in IL-10 production in BAL fluid compared with PBS con-
trols. Because LAPCs do not affect the T1 effector T cell re-
sponse (Th1 cells and CTLs) but contribute to the T2 effector 
T cell response (Th2 cells), the absence of any increase in   
IL-10 production in vivo might be anticipated. Neither T1 
nor T2 cytokine production in the BAL on day 8 was signifi-
cantly affected by DC transfer. Notably, LAPC-recipient mice 
showed exacerbated pulmonary pathology, as indicated by en-
hanced pulmonary eosinophilia (Fig. 8 F) and delayed viral 
clearance in the BAL (Fig. 8 G). Consistent with the observed 
enhanced CTL response, DC-recipient mice showed acceler-
ated viral clearance compared with control mice, with no dif-
ference in pulmonary eosinophilia (Fig. 8, F and G).
DISCUSSION
In this study, we describe a novel leukocyte population, des-
ignated LAPCs. Phenotypic, genetic, and morphological 
characterization distinguished LAPCs from other mouse im-
mune cells. Comparing the global gene expression profile of 
LAPCs with other immune cell types revealed that LAPCs 
are a distinct cell type, exhibiting a signature gene expression 
profile. Our studies with Rag-1/, Flt3L/, and IL-15/ 
mice  suggest  that  LAPCs  follow  a  distinct  developmental 
pathway from that of lymphocytes, DCs, and NK cells. Even 
though LAPCs express low levels of MHC-II before virus 
activation, the phenotypic characteristics of LAPCs do not 
conform with those of DC precursors, which express either 
CD11c or CD117 (c-kit; Naik et al., 2007). Two major DC 
precursor subtypes have been identified in mice, namely   
pro-DCs and pre-DCs, both of which have the potential 
to  differentiate  into  three  major  DC  subtypes  (pDCs, 
CD8+ cDCs, and CD8 cDCs). Pre-DCs are defined   
as CD11c+MHC-II and pro-DCs are defined as CD11c 
MHC-IILy6cCD117+. Given our FACS analysis of cell-
surface markers and the gene expression data, LAPCs are a 
CD11cLy6c+CD117 population, from which we infer 
that LAPCs likely are not DC precursors. Further analysis 
of  surface  marker  expression  also  distinguished  LAPCs   1446 A novel APC implicated in antiviral Th2 immunity | Yoo et al.
Figure 8.  Influenza virus–activated LAPCs modulate antiinfluenza T2 immunity in vivo. (A) Schematic diagram for in vivo adoptive transfer ex-
periments. (B) Weight loss was monitored daily and is shown as the percent weight loss relative to uninfected controls (means ± SEM). (D–G) On day 8 
after infection, mice (n = 6 per each group) were sacrificed and effector T cell responses in the DLN and BAL (C), antiinfluenza humoral immune responses 
in serum (D), cytokine and chemokine levels in BAL fluid (E), pulmonary eosinophilia (F), and viral titers in BAL fluid (G) were determined as described in 
Materials and methods. Data representative of two independent experiments are shown as means ± SEM and were analyzed using a Student’s t test. For 
cytokine and chemokine SearchLight proteome arrays, the values measured reflect dilution in 1 ml PBS to collect BAL fluid. The levels of detection for 
each cytokine and chemokine are described in Materials and methods. *, P < 0.05 for DC-recipient mice compared with PBS control mice; **, P < 0.05 for 
LAPC-recipient mice compared with PBS control mice.
et al., 2008). McGill et al. (2008) provided evidence that DCs 
also modulate the antiinfluenza CTL response in the lungs by 
TCR reengagement after the initial activation in the DLN. 
The predominant T2 response occurs later during infection, 
around day 7 after infection (Carding et al., 1993). This T2   
response may play a role in down-regulating the strong T1   JEM VOL. 207, July 5, 2010 
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Notch have been implicated in IL-4–independent Th2 lin-
eage commitment (Ito et al., 2005; Amsen et al., 2007). It is 
intriguing to speculate that LAPCs may provide Th2-polarizing 
signals through engagement of one of these receptors ex-
pressed on Ag-primed CD4+ T cells coordinated with T cell 
receptor signaling. The underlying mechanism of LAPC-
mediated Th2 polarization also remains to be addressed and   
is the subject of our ongoing investigations.
Collectively, our findings suggest that this novel leuko-
cyte cell population may play a pivotal role in modulating   
T2 immunity against pulmonary influenza A virus infec-
tion, which is implicated in both immunoprotection and   
immunopathology. Moreover, our data suggest a more wide-
spread involvement of these cells in different virus infections. 
Further insights into the in vivo function of LAPCs in differ-
ent virus infections and in response to challenge with differ-
ent pathogens and allergens may provide us with novel 
therapeutic targets for the treatment of different pathologies, 
including influenza A virus infection.
MATERIALS AND METHODS
Animals. C57BL/6J and OT-II Thy1.2 mice were bred and housed in the 
Toronto General Hospital animal facility. Rag-1/, A/J, DBA/2J, and 
BALB/c mice were purchased from the Jackson Laboratory. Flt3L/ and 
IL-15/  mice  were  purchased  from  Taconic.  OT-II  Thy1.1/1.2  mice 
were provided by J. Gommerman (University of Toronto, Toronto, Can-
ada). All mice were housed in a specific pathogen–free environment, and all 
experiments were approved by the Animal Care Committee of the Toronto 
General Research Institute.
Cell fractionation. Tissues (LNs, spleen, lungs, and thymus) were har-
vested and mechanically disrupted, followed by enzymatic digestion with 
collagenase D and DNase I (Roche). In brief, tissues were placed in cold 
PBS supplemented with 1 mM MgCl2 and 1.8 mM CaCl2 and compressed 
between two glass slides. These tissues were incubated at 37°C for 30 min 
with 1 mg/ml collagenase and 0.3 mg/ml DNase I. After incubation, DCs 
were dissociated from T cells by incubating with 1 mM EDTA for 10 min 
at room temperature. The cell suspension was filtered through a 70-µm 
mesh. RBCs were removed using ACK lysis buffer. PBMCs were collected 
from naive C57BL/6J mice. In brief, animals were sedated with isofluorane 
and up to 1 ml of peripheral blood was collected by cardiac puncture. 
PBMCs were isolated by Ficoll gradient centrifugation at 800 g for 20 min, 
and the PBMC layer was washed in cold PBS. BM cells were obtained 
from mice by flushing the marrow from femurs into cold PBS. RBCs were 
removed using ACK lysis buffer.
Virus infections. 8–12-wk-old mice were anesthetized by intraperitoneal 
inoculation with a mixture of ketamine and xylazine, and infected either by 
intranasal instillation with 50 µl PBS containing A/WSN/33 (H1N1) influ-
enza virus (a gift from G. Whittaker, Cornell University, Ithaca, NY) or the 
recombinant strain Western Reserve VACV (a gift from G. McFadden, Uni-
versity of Florida, Gainesville, FL), or for CVB3 infection, by intraperitoneal 
injection with 100 µl PBS containing CVB3 (a gift from P.P. Liu, University 
Health Network, Toronto, Canada). At the times after infection indicated in 
the figures, mice were sacrificed by cervical dislocation and the mediastinal, 
inguinal, and axillary LNs, lungs, and spleens were harvested and processed as 
previously described.
Antibody staining and flow cytometry. Fluorochrome-labeled mAbs spe-
cific for CD4 (GK1.5), CD8 (53-6.7), CD11b (M1/70), CD11c (N418), 
CD19 (MB19-1), CD34 (RAM34), CD40 (1C10), CD44 (1M7), B220/
CD45R (RA3-6B2), CD49b (DX5), CD62L (MEL-14), CD69 (H1.2F3), 
response, mediated by IL-4– and IL-10–induced suppression 
of  T1  effectors  (Scott  and  Kaufmann,  1991;  Romagnani, 
1997). T2 responses invoke antiinfluenza Ig production, which 
provides a protective effect against secondary viral challenge 
(DeKruyff et al., 1993; Yamamoto et al., 1996; Renegar et al., 
2004). T2 responses also contribute to immunopathology as-
sociated with primary influenza virus infection: a delayed viral 
clearance and conspicuous pulmonary eosinophilia are induced 
after adoptive transfer of antiinfluenza Th2 T cell clones 
(Graham et al., 1994), and T2 cytokines increase the severity 
of postinfectious encephalitis in mice exposed to influenza   
virus (Kaji et al., 2000). However, it is still unclear how this T2 
immunity is regulated in influenza A virus–infected animals.
In the presence of the Th1-polarizing cytokine IL-12, a 
short duration of TCR stimulation is sufficient to induce Th1 
polarization because IFN- production is rapidly induced. In 
contrast, a prolonged period of Ag stimulation has been sug-
gested to be required to induce Th2 polarization, because the 
capacity to produce IL-4 and IL-13 is acquired slowly (Iezzi   
et al., 1999; Kaech et al., 2002). An unresolved issue has been 
how TCR signaling in CD4+ T cells can be sustained for the 
extended time in the DLN of influenza virus–infected mice to 
successfully induce the antiviral Th2 response. In this study, we 
show that LAPCs can provide this signal to Ag-primed CD4+ 
T cells at later phases of infection. In our study, influenza   
virus–activated LAPCs could induce Th2 polarization of Ag-
primed CD4+ T cells in an Ag-specific manner, from which 
we infer that serial stimulation of influenza virus–specific CD4+ 
T cells by DCs and then LAPCs may occur to invoke a Th2 
response. Although we cannot rule out the possibility that 
constitutive migratory DCs from infected lung tissue may also 
be involved in Th2 effector polarization in the DLN at later 
stages after infection, these cells comprise 2% of the total DCs 
(140 cells) in the DLN after day 5 after infection (Legge and 
Braciale, 2003). Moreover, the data from our ex vivo study 
suggest that DCs isolated at a later phase after infection do not 
present viral Ag to cognate CD4+ T cells for optimal Th2   
polarization. Therefore, their relative contribution compared 
with LAPCs would appear to be minimal. This was further 
supported by our in vivo evidence showing that DCs isolated 
at later time points after infection from the DLN and spleen 
could only modulate the antiinfluenza CTL response in mice. 
Finally, recipient mice that received donor LAPCs but not 
DCs showed enhanced systemic and local antiinfluenza T2 im-
munity. Subsequently, these LAPC-recipient mice exhibited 
exacerbated pulmonary pathology, as indicated by augmented 
pulmonary eosinophilia and delayed viral clearance, suggesting 
that LAPCs, but not DCs, may play a pivotal role in modulat-
ing antiinfluenza virus T2 immunity in mice.
GATA-3 is a master regulator for Th2 lineage commit-
ment (Zheng and Flavell, 1997). GATA-3 expression may be 
regulated either by IL-4–dependent or –independent mecha-
nisms (Kubo, 2007). Our data show that LAPCs modulate 
GATA-3  expression  through  a  soluble  factor–independent 
mechanism, and demonstrate that cell–cell contact is critical 
for this LAPC-mediated regulation. Signals through OX40 or 1448 A novel APC implicated in antiviral Th2 immunity | Yoo et al.
Gene expression data were then subjected to further analysis. In the ini-
tial stage of analysis, the similarity of LAPCs to other immune cell types was 
determined. First, probes on the array that were greater than twofold different 
between LAPCs isolated from PBS- and influenza A virus–infected mice 
were removed, leaving 36,290 probes. This was done to only look at those 
probes that did not vary greatly between the LAPCs. The probes were then 
clustered using an unsupervised two-way hierarchical average linkage cluster-
ing algorithm with a Pearson centered distance metric. The resulting tree was 
examined for trends (Fig. 2).
In the second stage of analysis, a potential set of marker genes for LAPCs 
was sought. First, probes with consistently low signal measurements were re-
moved to decrease unnecessary noise. Each probe was averaged across repli-
cates for each cell type, and only those probes with an intensity measurement 
greater than the 30th percentile of all probes on a single chip in at least one of 
the cell types was allowed to pass through to the next stage of analysis. The 
resulting 36,589 probes were subjected to analysis of variance with a multiple 
testing Benjamini and Hochberg correction at the P < 0.05 significance level. 
30,072 probes were found to be significantly different among all 11 cell types. 
To identify LAPC-specific markers, only those probes that identified ex-
pressed genes that displayed a 10-fold difference between LAPCs and any 
other immune cell lineage in at least 5 out of the 10 possible comparisons 
were allowed. This final list of 279 expressed gene probes was examined by 
hand to find the best candidate unique genes, with the criterion that the genes 
are only expressed by LAPCs based on an Affymetrix intensity value >100. 
The data are presented as a heat map representing relative expression values as 
obtained after log10 transformation and median centering of the values across 
cell samples for each gene (Fig. S2).
Morphological analysis. For cytological analysis, FACS-sorted cells from 
either naive or influenza virus–infected mice were cytocentrifuged (600 rpm 
for 1 min) onto microscope slides and stained with modified Wright-Giemsa, 
and their morphology was examined by light microscopy (Axioskop 2; Carl 
Zeiss, Inc.).
Transmission electron microscopy. To visualize cells at the ultrastruc-
ture level, cells were fixed in 1% glutaraldehyde, 4% paraformaldehyde in 
0.1 M PBS buffer, pH 7.2 (overnight at 4°C), washed, and postfixed in 1% 
OsO4 for 1 h. After rinsing with 0.1 M PBS buffer, pH 7.2, dehydration 
steps were followed through graded ethanol series. Cells were embedded in 
EPON 812 (Ted Pella), polymerized for 48 h at 60°C. Ultrathin sections 
(80 nm) were collected onto 300 mesh copper grids, stained with 5% uranyl 
acetate and 0.03% lead citrate. Sections were visualized using a transmission 
electron microscope (H7000; Hitachi) operating at 75 kV. The images 
were captured using a digital 16-bit AMT camera. Representative images 
were selected and shown.
In vivo Ag uptake assay. Mice were anesthetized as described in Virus infec-
tions and infected by intranasal instillation with 50 µl PBS containing 500 PFU 
of A/WSN/33 influenza virus either with or without FITC-dextran (40 kD,   
1 mg/ml). On day 3 after infection, mice were sacrificed and cells were col-
lected from lungs. FACS analysis was performed to examine the percent popu-
lation of FITC+ cells, gating on T cells (TCR+), pDCs (mPDCA-1+CD11cint), 
and LAPCs (mPDCA-1+CD11cTCRB220) in lungs.
In vivo migration assay. LAPC migration was examined as previously de-
scribed (Legge and Braciale, 2003), with minor modifications. In brief, mice 
were anesthetized as described in Virus infections and infected with 50 µl PBS 
containing 500 PFU of A/WSN/33 influenza virus. On day 4 after infection, 
either 8 mM CFSE diluted in IMDM or medium alone was instilled intrana-
sally (50 µl/mouse) into individual mice to label all lung-infiltrated cells, in-
cluding LAPCs. 7 h after labeling, selected mice were sacrificed to examine 
the efficiency of in vivo CFSE labeling using FACS analysis. On day 8 after 
infection, mice were sacrificed, the DLNs and spleens were harvested, and 
the percent population of CFSE+ cells, gating on LAPCs, was examined by 
FACS analysis.
CD80 (16-10A1), CD86 (GL1), CD117 (2B8), CD122 (5H4), NK1.1 
(PK136), F4/80 (BM8), Gr1 (RB6-8C5), TCR (H57-597), Thy1.1 (HIS51), 
Thy1.2 (53-2.1), IL-2 (JES6-5H4), IL-4 (11B11), IL-10 (JES5-16E3), IFN- 
(XMG1.2), and MHC-II (I-A/E; M5/114.15.2) were obtained from eBiosci-
ence. A FITC-conjugated mAb to mPDCA-1 (JF05-1C2.4.1) was purchased 
from Miltenyi Biotec. Anti-CD79b (HM79b), -CD138 (281-2), -TCR 
(GL3), and –GATA-3 (L50-823) mAbs were purchased from BD. A CXCR3 
(220803)-specific mAb was obtained from R&D Systems, and a mAb specific 
for DEC 205 (NLDC-145) was purchased from BMA Biomedical AG. Flow 
cytometry was performed on FACSCalibur and FACSAria instruments (BD), 
with optimal compensation set for four-color staining. The data were analyzed 
using FlowJo software (Tree Star, Inc.).
To examine cytokine production, cells were restimulated with 50 ng/ml 
PMA, 500 ng/ml ionomycin (Sigma Aldrich), and GolgiPlug (BD) for 4 h, 
washed with FACS buffer (PBS supplemented with 2% FBS), and surface 
stained with the appropriate identifier fluorochrome-conjugated mAbs.   
After fixation and permeabilization with Cytofix/Cytoperm buffer (BD), 
intracellular staining was performed using mAbs for each cytokine followed 
by FACS analysis.
Sample processing and microarray analysis for LAPCs. Groups of 
mice were either mock (PBS)-infected (n = 10) or infected with influenza 
virus (500 PFU; n = 5) by intranasal instillation and sacrificed on day 8   
after infection, and DLNs were harvested. LAPCs were sorted by FACS 
and total RNA was prepared using either the RNeasy Mini or Micro Kit 
(QIAGEN). RNA was processed using a two-round RNA amplification 
protocol described by Affymetrix (GeneChip Expression Manual Small 
Sample 2). The preparation of cDNA from RNA, sample hybridization, 
and scanning of the GeneChip Mouse Genome 430 2.0 Array (Affyme-
trix) were performed at the Center for Applied Genomics Microarray   
Facility  (Hospital  for  Sick  Children,  Toronto,  Canada)  in  accordance 
with  the  procedures  established  by  Affymetrix.  Microarray  data  for 
LAPCs have been deposited in the Gene Expression Omnibus under ac-
cession no. GSE17726.
Data processing and integration with public data. Raw expression 
data for LAPCs were imported into R and Bioconductor for initial quality 
assessment using the arrayQuality package. Once satisfied that there were 
no technical issues, LAPC data were combined with several publicly avail-
able datasets of mouse immune system cell types. Included were mouse 
splenic gene expression datasets performed on the GeneChip Mouse Ge-
nome 430 2.0 Array by Robbins et al. (2008). Cell types included CD11b+ 
DCs (n = 2), CD8+ cDCs (n = 2), pDCs (n = 2), B cells (n = 3), NK cells 
(n = 2), and CD8+ T cells (n = 2). These data have been deposited in the 
Gene Expression Omnibus under accession no. GSE9810. In addition, 
macrophage gene expression data from young mice (n = 3; Chelvarajan   
et al., 2006) were collected from the National Cancer Institute caArray 
(http://caarray.nci.nih.gov/) along with control CD4+ T cell gene expres-
sion data (n = 2; microarray data have been deposited in the Gene Expres-
sion Omnibus under accession nos. GSM44979 and GSM44982; Fontenot 
et al., 2005). Finally, we included two samples of mast cells from a gene ex-
pression dataset that is part of the mouse gene atlas project (http://biogps 
.gnf.org/#goto=welcome; microarray data have been deposited in the Gene   
Expression Omnibus under accession nos. GSM258711 and GSM258712) and 
two samples of granulocytes from another dataset (microarray data have 
been deposited in the Gene Expression Omnibus under accession nos. 
GSM149595 and GSM149596). Gene expression data from all cel files were 
imported into GeneSpring analysis software (version 10; Agilent Technolo-
gies). All data were preprocessed using the RMA algorithm (Irizarry et al., 
2003). Data were further normalized to the median expression measure for 
each gene across all samples and logged (base 2).
As a starting point, probes used in a previous paper (Table 2 in Robbins 
et al. [2008]) were used as a cassette of control genes to compare expression 
across all cell types. In addition to this, several other probes of interest were 
also included (Table S1).JEM VOL. 207, July 5, 2010 
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3 (5 × 105 cells/mouse) after infection by i.v. injection. Weight loss was moni-
tored until day 8 after infection and shown as the percent weight loss relative 
to day 0 control mice.
Influenza virus titration. Viral titers in BAL fluid were determined using 
a Madin-Darby canine kidney (MDCK) cell plaque assay. On day 8 after in-
fection, mice were euthanized and BAL fluid was harvested. MDCK cells 
were seeded in MEM in individual wells of 6-well plates until confluent. 
10-fold serial dilutions of BAL fluid were prepared in serum-free MEM.   
A total of 200 µl of each dilution was added to individual wells (in duplicate) 
for 30 min at 37°C. Cells were then overlaid with 3 ml of 1× MEM contain-
ing 0.65% agarose, antibiotics, l-glutamine, and 1 µg/ml trypsin. 40 h after 
incubation at 37°C, cells were fixed with 2 ml Carnoy’s fixative (methanol/
glacial acetic acid, 3:1) for 30 min. The agarose overlay was then removed 
and fixed monolayers were stained by adding crystal violet prepared in 20% 
ethanol to permit visualization of viral plaques for counting.
Influenza virus–specific antibody ELISA. Serum was collected from 
either naive mice or influenza virus–infected mice on day 8 after infection 
and examined for influenza virus–specific antibody responses by ELISA.   
In brief, 96-well plates were coated overnight at 4°C with 100 µl (106 PFU) 
of heat-inactivated (58°C) A/WSN/33 influenza virus. The plates were 
washed twice with PBS supplemented with 0.05% Tween-20 (PBST) and 
incubated with 100 µl of 2% BSA in PBST for 1 h at room temperature. 
After washing the plates with PBST, 100 µl of diluted serum was added to 
each well, in duplicate, and incubated for 2 h at room temperature. Bound 
antibodies were detected by the incubation of horseradish peroxidase– 
conjugated  anti–mouse  IgG1  (1:1,000),  IgG2a  (1:1,000;  BD),  IgG2b 
(1:1,000), IgA (1:8,000; SouthernBiotech), or IgE (1:1,000; AbD Serotec) 
antibodies at room temperature. After 1 h, the plates were washed with 
PBST, and 100 µl of 3,3,5,5-tetramethylbenzidine substrate solution 
(Sigma-Aldrich) was added into each well and incubated for 30 min. The 
enzyme reaction was stopped by adding 100 µl of 2N H2SO4 and OD val-
ues were determined at 450 nm using a plate reader (SpectraMax 384 Plus 
UV-VIS; MDS Analytical Technologies).
Determination of cell numbers and cytokine levels in BAL. Mice 
were sacrificed at the times after infection indicated in the figures. Lungs 
were excised together with trachea and flushed with 1 ml PBS using a blunted 
23-gauge needle inserted into the trachea. Cells were collected by centrifuga-
tion at 400 g for 5 min. The supernatants were collected and stored frozen at 
80°C until analyzed for cytokine and chemokine expression using proteome 
arrays (SearchLight; Aushon BioSystems). The limits of detection of each cyto-
kine and chemokine in this assay are as follows: eotaxin, 0.1–200 pg/ml; IFN-, 
3.9–8,000  pg/ml;  IL-5,  0.8–1,600  pg/ml;  IL-4,  0.4–800  pg/ml;  IL-12p70,   
0.4–800  pg/ml;  IL-13,  0.8–1,600  pg/ml;  TNF,  1.6–3,200  pg/ml;   
IL-10, 0.8–1,600 pg/ml; and CXCL10/IP-10, 0.4–800 pg/ml. The cells 
were resuspended and RBCs were lysed with ACK lysis buffer. Cells were 
washed twice with PBS and resuspended in FACS buffer. Cell numbers were 
counted using a hemocytometer. Cells were stained with a panel of fluoro-
chrome-conjugated mAbs and analyzed using a FACSCalibur.
[3H]Thymidine incorporation assay. C57BL/6J mice were infected by   
intranasal instillation with either 500 PFU of A/WSN/33 or A/WSN/OVA(II) 
virus. DCs (CD11c+) were isolated from the DLNs on day 3 after infection and 
from the LAPCs on day 8 after infection by FACS sorting. Isolated APCs were 
-irradiated (2,000 rads) and incubated together with naive OT-II T cells in 
96-well plates (105 APCs/well; 5 × 104 OT-II T cells/well). As positive con-
trols, OT-II T cells were incubated together with OVA323–339 peptide pulsed 
-irradiated APCs (DCs or LAPCs). 78 h after incubation, 1 µCi [3H]thymidine 
was added to each well and cells were incubated for a further 18 h. [3H]Thymidine 
incorporation was analyzed with a -scintillation counter.
Statistical analysis. Data were analyzed by an unpaired two-tailed Stu-
dent’s t test unless otherwise noted in the figure legends. P < 0.05 was con-
sidered significant. Data are expressed as either means ± SD or SEM.
DEAD assay. C57BL/6J mice were infected by intranasal instillation with 
500 PFU of either A/WSN/33 or A/WSN/OVA(II) virus. A/WSN/
OVA(II)  virus  was  provided  by  D.  Topham  (University  of  Rochester, 
Rochester, NY; Chapman et al., 2005). DCs (pDCs, mPDCA-1+CD11cint; 
cDCs, CD11chighB220) and LAPCs were sorted from the DLNs on days 3 
and 8 after infection, respectively, by FACS. To optimize culture condition, 
sorted  APCs  were  co-cultured  with  naive  OT-II  T  cells  with  various   
APC/T cell ratios (1:10, 1:4, 1:3, and 1:2 ratios were tested). To examine for 
their ability to activate OVA-specific OT-II T cells, at 48, 72, and 96 h after in 
vitro co-culture, samples were harvested and T cell activation was examined 
by intracellular IL-2 staining for T cells. Finally, a 1:2 ratio between   
APCs/T cells (5 × 104 APCs/well; 105 OT-II T cells/well) was selected as 
the optimized culture conditions. At 96 h after incubation, cells were either 
stimulated with 50 ng/ml PMA, 500 ng/ml ionomycin, and GolgiPlug (BD) 
for 4 h, or were treated with GolgiPlug only for 4 h. Cells were collected, 
washed, and surface stained with fluorochrome-conjugated anti-CD4 and 
Thy1.2 mAbs. After fixation and permeabilization, intracellular staining was 
performed using a PE-conjugated IL-2–specific mAb. Data are presented as 
the percent population of IL-2–positive cells in total OT-II.
In vivo tracking assay. Mice (n = 10) were infected by intranasal instilla-
tion with 500 PFU of influenza virus, and activated LAPCs were then iso-
lated from the DLNs on day 6 after infection. FACS-sorted cells were stained 
with CFSE (Invitrogen) according to the manufacturer’s instructions, and 
CFSE-labeled LAPCs were adoptively transferred by i.v. injection (106 cells/
mouse) into recipient influenza virus–infected mice (n = 2; 500 PFU) on day 
6 after infection. 24 h after transfer, the mice were euthanized and the DLNs 
were harvested and frozen in Tissue-Tek solution (Sakura). Tissues were 
cryosectioned  (20  µm)  and  thin-section  slides  were  prepared.  Slides   
were warmed to room temperature and washed in PBS, and the sections were 
fixed in 1:1 methanol/acetone at –20°C for 15 min. The thin sections were 
then dried and frozen at –70°C for 30 min. Tissue sections were washed in 
PBS and blocked with 0.2% gelatin at 4°C overnight. Sections were stained 
with anti-B220–APC antibody (1:50; BD). Slides were examined by a laser 
scanning confocal microscope (FluoView 1000; Olympus). Final image pro-
cessing was performed using the FluoView viewer (version 1.7.a; Olympus).
CD4+ T cell isolation. LN-derived CD4+ T cells were isolated from either 
naive OT-II Thy1.2 or OT-II Thy1.1/1.2 mice by depletion of non-CD4+ 
T cells (negative selection) using a CD4+ T cell isolation kit (Miltenyi Bio-
tec). To isolate in vivo Ag-primed OT-II T cells, purified Thy1.1+ OT-II   
T cells were transferred into Thy1.2+ C57BL/6J mice by i.v. injection. 24 h 
after adoptive transfer, recipient mice were infected intranasally with 500 PFU 
of A/WSN/OVA(II) virus. On day 5 after infection, mice were sacrificed 
and their DLNs were harvested. Thy1.1+CD4+ cells were isolated from the 
DLNs by FACS sorting. The isolated CD4+ T cells were subjected to FACS 
analysis to confirm purity (MACS, 90%; FACS, ≥97%).
Transwell experiment. To examine whether LAPCs induce effector T cell 
generation through direct cell contact or through release of soluble factors, 
Transwell experiments were performed. In vivo primed OT-II T cells were 
added to individual wells (105 cells/well) of a 96-well Transwell plate in the 
lower chamber and influenza virus–activated LAPCs were introduced into 
individual wells (5 × 104 cells/well) in the upper chamber. Cells were sepa-
rated with a 0.4-µm pore membrane (Costar; Corning), which allows diffu-
sion of small molecules, such as cytokines, but not cells. All experiments were 
performed in triplicate. After 24 h, T cells are harvested from the lower com-
partments and assayed for IL-4 and IFN- production by FACS analysis.
Adoptive transfer of influenza virus–activated LAPCs and DCs. Mice 
were infected with 300 PFU of A/WSN/33 virus as described. On day 8 after 
infection, mice were sacrificed and influenza virus–activated LAPCs or DCs 
were harvested from the DLNs and spleens by FACS sorting. The isolated cells 
were subjected to FACS analysis to confirm purity (≥98%). 200 µl of sterile 
PBS buffer either with or without sorted cells was injected into A/WSN/33 
virus–infected (300 PFU) recipient mice on days 1 (3 × 105 cells/mouse) and 1450 A novel APC implicated in antiviral Th2 immunity | Yoo et al.
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